New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:18 EDTBCRXBioCryst upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo upgraded BioCryst to Outperform saying the stock is not pricing in the likelihood of success for BCX-4161 in Hereditary Angioedema. Wells raised its price target range for shares to $17-$19 from $8-$9.
News For BCRX From The Last 14 Days
Check below for free stories on BCRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BCRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use